Search

Search Results

• Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia

  Nadezhda Viktorovna Kurkina, E.A. Repina, P.V. Volkova, A.A. Repin

  209-212

  03.03.2023

• Ibrutinib as First-Line Therapy in High-Risk Chronic Lymphocytic Leukemia: Case Reports

  Nadezhda Viktorovna Kurkina, E.A. Repina

  488-495

  01.10.2021

• Prediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia

  Olga Borisovna Kalashnikova, I.S. Moiseev, T.L. Gindina, E.A. Izmailova, M.O. Ivanova, E.V. Kondakova, N.B. Mikhailova, A.D. Kulagin

  466-476

  01.10.2021

• Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia

  Elena Aleksandrovna Stadnik, N.S. Timofeeva, V.V. Strugov, A.Yu. Zaritskey

  42-49

  01.01.2018

• Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

  Evgenii Aleksandrovich Nikitin, E.A. Dmitrieva, M.A. Panteleev, E.I. Emelina, V.L. Ivanova, Yu.B. Kochkareva, E.G. Arshanskaya, I.E. Lazarev, E.E. Markova, L.A. Mukha, N.G. Novitskaya, M.M. Pankrashkina, V.V. Glazunova, A.V. Shubina, S.A. Chernysh, N.K. Khuazheva, E.V. Naumova, S.A. Lugovskaya, M.E. Pochtar’, T.N. Obukhova, O.Yu. Vinogradova, G.E. Gendlin, V.V. Ptushkin

  271-281

  01.07.2017

• Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I

  S.S. Bessmeltsev

  237-257

  01.07.2013